A French study analyzed clinical data of pretreated ALK-positive patients with advanced non-small cell lung cancer (NSCLC) and examined the efficacy of next-generation ALK inhibitors –⁠ brigatinib, followed by lorlatinib –⁠ in real-world clinical practice.

Debridement is an integral part of chronic wound treatment. Currently, the most common method is mechanical debridement, which involves the use of sharp tools or abrasive materials to remove necrotic tissue. However, this method can be painful, imperfect, and associated with the risk of damaging healthy tissue. New and gentler methods are emerging, promising improved therapeutic outcomes, such as the use of a water microjet.

We invite you to watch a webinar dedicated to the topic of nutrition in old age. The impetus for its creation was the fact that from September 1, 2020, physicians specializing in geriatrics are allowed to prescribe outpatient sipping to ensure early nutritional intervention for malnourished patients.

The American Society of Hematology (ASH) published current guidelines for immune thrombocytopenia (ITP) at the end of 2019, where a panel of experts attempted to define evidence-based recommendations for the management of these patients.

At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early June 2022, the final results of the J-ALTA clinical study were presented. So how did brigatinib perform in the treatment of patients with ALK-positive NSCLC who were refractory to alectinib?

Sotorasib is the first targeted drug approved for the treatment of metastatic non-small cell lung cancer (NSCLC) with the G12C mutation of the KRAS oncogene. The newly published study presented below investigated its intracranial activity.

Even in a market dominated by generics, eletriptan 40 mg is among the most clinically effective and cost-efficient triptans for the acute treatment of migraine attacks. This was demonstrated by a systematic literature review focused on the pharmacoeconomic evaluation of this therapy, published by American authors in 2015. Its high cost-effectiveness may be due to its strong efficacy with a reduced need for additional treatment.

An article published in the March issue of the prestigious journal JAMA Neurology summarizes the findings of an analysis of the course of COVID-19 in patients with multiple sclerosis in North America. Which patients are at greater risk of severe infection?

In contemporary armed conflicts, limb injuries account for more than half of all injuries. In addition to the characteristically high incidence of infectious complications, injuries associated with military medicine also carry a high risk of thromboembolic disease. This is demonstrated by a study assessing the incidence of thromboembolic disease in American soldiers over 10 years of military operations in the Middle East.

Treating hypertension to recommended target blood pressure values often requires a combination of three antihypertensives. By simply combining these three substances into a single pill, it is possible to increase treatment adherence, reduce overall mortality in hypertensive patients, and lower healthcare costs within one year. This is demonstrated by a freshly published Italian real-world study.

At the XXVIII. Pařízek Days held in Ostrava, on the afternoon of March 17, 2022, Dr. Anna Maria Pejková from the 4th Internal Clinic of the University Hospital Hradec Králové presented 3 case reports of acquired hemophilia A.

Managing symptoms associated with advanced cancer has a significant impact on patients' quality of life and influences decisions about appropriate therapy for an individual patient. An international team of authors conducted a retrospective analysis of 3 clinical trials of the anti-epidermal growth factor receptor (EGFR) antibody panitumumab in the treatment of metastatic colorectal carcinoma (mCRC) and assessed the relationship between tumor response to treatment and the occurrence of symptoms associated with the tumor.

More than 2 million people worldwide undergo maintenance hemodialysis in outpatient centers. Effective prevention of the spread of infection caused by the SARS-CoV-2 coronavirus within the care provided by hemodialysis centers is essential for the smooth provision of dialysis to patients with end-stage renal disease. The following work from experts in Boston is based on their experiences as well as recommendations from the American Society of Nephrology (ASN) and the Centers for Disease Control and Prevention (CDC).

Polatuzumab Vedotin is a conjugate of a cytostatic agent and an antibody against CD79b, a component of the B-lymphocyte receptor typically expressed by diffuse large B-cell lymphoma (DLBCL) cells. In combination with bendamustine and rituximab (pola-BR), this drug is administered in the 3rd and subsequent lines of treatment for relapsed or refractory (R/R) DLBCL. If allogeneic hematopoietic stem cell transplantation (HSCT) is not feasible, patients with R/R DLBCL generally have a very poor prognosis, with limited further treatment options. However, at the 61st American Society of Hematology (ASH) congress held in December 2019 in Orlando, promising results were presented from extended follow-up of patients treated in clinical studies with the pola-BR combination.

The work of a team of German and Dutch authors presents data on the real clinical use of 10% subcutaneous immunoglobulin facilitated by hyaluronidase (fSCIG) in elderly patients with primary (PID) or secondary (SID) immunodeficiency.